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Treat-and-Extend versus Monthly Regimen in
Neovascular Age-Related Macular
Degeneration
Results with Ranibizumab from the TREND Study
Ruﬁno Silva, MD, PhD,1,2,3 András Berta, MD, PhD,4 Michael Larsen, MD, DMSc,5 Wayne Macfadden, MD,6
Chrystel Feller, PhD,6 Jordi Monés, MD, PhD,7 on behalf of the TREND Study Group*
Purpose: To evaluate the efﬁcacy and safety of ranibizumab 0.5 mg treat-and-extend (T&E) versus monthly
regimens in patients with neovascular age-related macular degeneration (nAMD) from the TReat and extEND
(TREND) study.
Design: A 12-month phase 3b visual acuity (VA) assessor-masked, multicenter, randomized, interventional
study.
Participants: Six hundred ﬁfty patients.
Methods: Treatment-naïve nAMD patients (age, 50 years) were randomized 1:1 to receive either a ranibi-
zumab 0.5 mg T&E (n ¼ 323) or monthly (n ¼ 327) regimen.
Main Outcomes Measures: The primary objective was to show noninferiority of ranibizumab 0.5 mg T&E
versus monthly regimen, as assessed by the change in best-corrected VA (BCVA) from baseline to the end of the
study. Secondary objectives included change in retinal central subﬁeld thickness (CSFT) from baseline to the end
of study, treatment exposure, and safety.
Results: Overall, 89.8% (T&E) and 90.2% (monthly) of patients completed the study. Patient demographic
and baseline characteristics were well balanced between the 2 treatment groups. The T&E regimen was non-
inferior (P < 0.001) to the monthly regimen, with a least squares mean BCVA change from baseline of 6.2 versus
8.1 letters to the end of study, respectively. In both treatment groups, most BCVA improvements occurred during
the ﬁrst 6 months and were maintained until the end of the study. The mean change in CSFT from baseline to the
end of study was 169.2 mm and 173.3 mm in the T&E and monthly groups, respectively. Fewer injections were
required in patients receiving the T&E (8.7) versus monthly (11.1) regimen, with mean number of postbaseline
visits of 8.9 and 11.2, respectively. Types and rates of adverse events were comparable between the treatment
groups.
Conclusions: Ranibizumab 0.5 mg administered according to a T&E regimen was statistically noninferior and
clinically comparable with a monthly regimen in improving VA from baseline to the end of study. No new safety
signals for ranibizumab were identiﬁed. Ophthalmology 2018;125:57-65 ª 2017 American Academy of Ophthal-
mology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Supplemental material available at www.aaojournal.org.Neovascular age-related macular degeneration (nAMD) is
one of the major causes of severe vision loss in developed
countries, particularly in the population 50 years of age and
older.1,2 Overall, it accounts for 8.7% of total blindness
worldwide and for 50% to 60% of new cases of blindness
every year.1e7
Antievascular endothelial growth factors (VEGFs) are
considered the ﬁrst-line therapy for the treatment of patients
with nAMD.8 Ranibizumab 0.5 mg (Lucentis; Novartis
Pharma AG, Basel, Switzerland; and Genentech, Inc,
South San Francisco, CA) was the ﬁrst approved anti-
VEGF for the treatment of choroidal neovascularizationª 2017 American Academy of Ophthalmology. Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).(CNV) secondary to AMD based on the results of 2 phase 3
clinical studies: the Minimally Classic/Occult Trial of the
Anti-VEGF Antibody Ranibizumab in the Treatment of
Neovascular Age-Related Macular Degeneration (AMD)9
and Anti-VEGF Antibody for the Treatment of Predomi-
nantly Classic Choroidal Neovascularization in Age-Related
Macular Degeneration.10 In these studies, monthly
ranibizumab injections resulted in substantial and
sustained best-corrected visual acuity (BCVA) improve-
ments over 2 years. However, a monthly treatment regimen
may pose the inconvenience of more frequent dosing visits,
thus increasing the overall treatment burden for patients.57http://dx.doi.org/10.1016/j.ophtha.2017.07.014
ISSN 0161-6420/17
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ranibizumab, pro re nata (PRN), was evaluated in the Pro-
spective OCT Study with Lucentis for Neovascular AMD,11
Comparison of AMD Treatments Trials,12,13 and the Phase
III, Double-Masked, Multicenter, Randomized, Active
Treatment-Controlled Study of the Efﬁcacy and Safety of
0.5 mg and 2.0 mg Ranibizumab Administered Monthly or
on an As-Needed Basis (PRN) in Patients with Subfoveal
Neovascular Age-Related Macular Degeneration,14 in which
ranibizumab administered PRN showed an improvement in
visual outcomes with fewer injections compared with
monthly treatment. However, the burden of monthly
monitoring visits remained unaddressed. Furthermore, both
monthly and reactive PRN regimens may lead to
overtreatment or undertreatment, thus adding to challenges
to the management of patients with nAMD.
To minimize both clinic visit and injection frequency,
proactive dosing regimens that allow extension of visit
intervals, such as treat and extend (T&E),15 were evaluated.
Several studies have evaluated T&E regimens and found the
principle to be a feasible option for the treatment of patients
with nAMD.16,17 However, few randomized controlled trials
have evaluated the T&E regimen versus a monthly
regimen.18,19 Herein, we report 12-month results of the
TREND study, which evaluated the efﬁcacy and safety of a
ranibizumab-0.5 mg T&E regimen versus a monthly
regimen in patients with nAMD, to assess whether T&E can
result in similar visual beneﬁts as observed with the monthly
regimen while reducing injection burden for patients, cli-
nicians, and healthcare systems.Methods
Study Design
The TREND was a 12-month phase 3b visual acuity (VA)
assessor-masked, multicenter, interventional study in patients with
newly diagnosed nAMD. Monthly treatment has demonstrated
maximum visual outcomes in several studies and therefore was
selected as a comparator for the T&E dosing regimen in this study.
Between December 2013 and November 2015, 650 treatment-
naïve patients with visual impairment resulting from active CNV
secondary to AMD were enrolled at 90 centers across 18 countries
(Table in Appendix 2, available at www.aaojournal.org). The study
protocol was reviewed and approved by an independent ethics
committee or institutional review board at each center. The study
was conducted in accordance with the ethical principles of the
Declaration of Helsinki. Written informed consent was obtained
from each patient at screening. The study is registered at
clinicaltrials.gov with identiﬁer NCT01948830.
Patient Selection
The study population consisted of treatment-naïve patients 50 years
of age or older with visual impairment resulting from active CNV
secondary to AMD conﬁrmed by presence of active leakage of
CNV detected by ﬂuorescein angiography, color fundus photog-
raphy, or both. Other key inclusion criteria were total area of
ﬁbrosis comprising less than 50% of the lesion area and BCVA
score between 23 and 78 Early Treatment Diabetic Retinopathy
Study (ETDRS) letters at a distance of 4 m (approximately 20/32
and 20/320 Snellen equivalent, respectively).58Patients were excluded if they had any type of advanced,
severe, or unstable disease, including any medical condition that
can bias assessment or put the patient at special risk; history of
stroke or myocardial infarction within 3 months before screening
or an uncontrolled systolic blood pressure of more than 160 mmHg
or diastolic blood pressure of more than 100 mmHg; prior treat-
ment of the study eye with anti-VEGF or verteporﬁn photodynamic
therapy or corticosteroids within 6 months before screening or
intraocular surgery within 3 months before screening; history of
focalegrid laser photocoagulation with involvement of the macular
area; or uncontrolled glaucoma or atrophy or ﬁbrosis in the study
eye (details on the complete inclusion and exclusion criteria are
provided in Appendix 3, available at www.aaojournal.org).
Randomization and Treatment
Patients were randomized 1:1 to receive either the ranibizumab
0.5-mg T&E or monthly regimen. Patients in the T&E group
received 2 initial monthly ranibizumab injections at baseline
(day 1) and month 1. After 1 month, visits in the T&E group were
scheduled based on disease activity as assessed by VA and OCT
criteria. Patients were treated at monthly intervals until disease
activity was resolved, as assessed by spectral-domain OCT
according to the investigator’s judgment (i.e., no intraretinal or
subretinal ﬂuid). If disease activity was not present, the next visit
was scheduled in 6 weeks (i.e., the treatment interval, deﬁned as
the period between 2 ranibizumab injections, was extended by 2
weeks); however, if disease activity was present, the interval to the
next visit was not extended and thus was scheduled in 4 weeks
(1 month). The treatment interval could be extended by 2 weeks at
each visit as long as there was no disease activity, with a maximum
of a 12-week treatment interval. During the course of the study, if
disease activity was present, the treatment interval was shortened
by 2 weeks, but never to fewer than 4 weeks. The patient was
treated at this interval until no disease activity was present, after
which an extension of 2 weeks was reactivated. The possibility to
extend the interval between treatments was limited to 2 attempts. If
disease activity recurred, the visit schedule was shortened by 2
weeks and ﬁxed on this interval up to the end of the study.
However, if disease activity was present along with visual
impairment, the treatment interval was allowed to shorten by 4
weeks instead of 2 weeks based on the investigator’s judgment
(Fig 1). In the monthly regimen group, treatment visits were
scheduled at monthly intervals up to the end of the study.
Treatment Masking
In this study, the VA assessor who assessed the parameters for the
primary end point was masked to the treatment regimen and was
not allowed to perform any additional study tasks. The BCVA
assessments were performed ﬁrst before conducting any other
assessments and were recorded and archived.
Objectives
The primary objective of the study was to demonstrate non-
inferiority of the ranibizumab 0.5-mg T&E regimen to the monthly
regimen in patients with nAMD as assessed by change in BCVA
from baseline to the end of study. For the primary analysis, a
noninferiority margin of 5 letters was applied. This was selected
based on clinical relevance, because 5 letters constitute 1 line on
the ETDRS chart. In the Comparison of AMD Treatments Trials
and the Phase III, Double-Masked, Multicenter, Randomized,
Active Treatment-Controlled Study of the Efﬁcacy and Safety of
0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an
As-Needed Basis (PRN) in Patients with Subfoveal Neovascular
Age-Related Macular Degeneration, noninferiority margins were
Figure 1. Diagram showing the study design. *Example of possible dosing
schedule of a patient with extended visits. Bsl ¼ baseline; D ¼ day;
EOS ¼ end of study; EOT ¼ end of treatment; Ext ¼ extension; R ¼
randomization; T&E ¼ treat and extend; wk ¼ week.
Silva et al  T&E vs. Monthly Ranibizumab in nAMD4 to 5 letters and were based on a similar rationale regarding
clinical relevance for a fewer than 1-line difference.
Secondary objectives included evaluation of the efﬁcacy of
ranibizumab 0.5 mg (T&E vs. monthly) as assessed by (1) change
in BCVA from baseline to the end of study; (2) average change in
BCVA from baseline to month 1 through the end of study; (3)
proportion of patients with categorized BCVA gain of 1 letter or
more, 5 letters or more, 10 letters or more, 15 letters or more, and
30 letters or more; loss of fewer than 5, fewer than 10, and fewer
than 15 letters from baseline to the end of study; and BCVA of 73
letters or more (20/40 Snellen equivalent) over the study period;
(4) change in retinal central subﬁeld thickness (CSFT), presence
of a ﬂuid-free macula (e.g., no intraretinal or subretinal ﬂuid), and
presence of active CNV leakage from baseline to the end of study;
(5) treatment frequency and average dosing interval until the end
of study; and (6) safety of both dosing regimens of ranibizumab
0.5 mg.Study Assessments
All efﬁcacy assessments were performed on the study eye. The
BCVA was assessed at every visit using the ETDRS VA testing
protocol at a starting distance of 4 m. The change in CSFT was
assessed at every visit using spectral-domain OCT and was eval-
uated by a central reading center to determine the status of disease
activity. Fluorescein angiography was performed after color fundus
photography to assess the choroid and retinal vasculature of the
study eye. These assessments were performed by a trained tech-
nician at the sites at screening and at the end of study, and the
images were evaluated by a central reading center. At all other
scheduled visits, the images of the study eye were obtained at the
investigator’s discretion and were not provided to the reading
center. Data on treatment frequency and average dosing interval
were collected over the 12-month duration of the study.
Safety assessments included physical examination; vital signs;
ophthalmic assessments; and type, frequency, and severity of
adverse events (AEs). All ocular AE assessments were performed
on both eyes. Intraocular pressure (IOP) was measured at screening
and at the end of study in both eyes. In the study eye, pretreatment
IOP was assessed at every scheduled visit from day 1, and post-
treatment IOP was assessed after each intravitreal ranibizumab
injection. If IOP was 25 mmHg or more in the study eye and nottransient during the study period, it was treated based on the
investigator’s discretion. Intravitreal ranibizumab injection was not
recommended unless normalization of the IOP was achieved.
Statistical Analysis
The hypothesis testing with respect to noninferiority of BCVA was
performed using an analysis of covariance (ANCOVA) model
including treatment group as factor and baseline BCVA as
continuous variable. The primary analysis was performed on the
full analysis set using the last observation carried forward principle
for imputing missing BCVA values at the end of the study. The full
analysis set comprised all patients to whom a treatment regimen
was assigned.
Assuming a standard deviation (SD) of 15 ETDRS letters in the
T&E and monthly groups, with a difference of 1.5 in mean change
in BCVA from baseline in favor of the monthly regimen, and by
applying an ANCOVA model, a sample size of 322 patients per
treatment group was considered (to account for loss of information
resulting from missing data, the sample size was increased by 10%
from 290 to 322). With this sample size, the resulting power for
ANCOVA was 80% to establish noninferiority of the T&E regimen
versus the monthly regimen at a 1-sided 2.5% level for a non-
inferiority margin of 5 letters. The least squares (LS) mean and
standard errors for each treatment group and treatment difference
along with their 95% conﬁdence intervals were presented. Two-
sided P values were presented for treatment difference.
The analysis of the secondary efﬁcacy objectives was based on
the full analysis set. At all the time points assessed, efﬁcacy var-
iables (BCVA and CSFT) were presented graphically, and
descriptive statistics were provided based on absolute values and
changes from baseline. Because of the study design, the data from
patients randomized to the monthly regimen were recorded at
monthly scheduled visits only. In patients randomized to the T&E
group, data were recorded on scheduled visits for treatment. These
visits were based on a biweekly visit grid; however, each patient
had her or his own set of scheduled visits, determined based on
disease activity or visual impairment. Data for the patients in the
T&E group were mapped to monthly visits.
Changes in BCVA and CSFT from baseline to the end-of-study
visit were compared between treatment groups using ANCOVA
models (with the baseline covariate) or the t test. Categorical
variables were presented as the number and percentage of patients
in each category. Continuous variables were summarized using
descriptive statistics (e.g., number, mean, SD, median, minimum,
and maximum). Safety was analyzed using observed data from the
safety set that consisted of all patients who received at least
1 application of study treatment and underwent at least 1 post-
baseline safety assessment.Results
Patient Demographic and Baseline Ocular
Characteristics
A total of 650 patients were randomized to receive the ranibizumab
0.5 mg T&E (n ¼ 323) or monthly (n ¼ 327) regimen. Overall,
89.8% of patients in the T&E group and 90.2% in the monthly
group completed the study. The most frequent reasons for study
discontinuation were withdrawal of consent (n ¼ 31) and AEs
(n ¼ 11; Fig 2). The safety set included 649 patients (T&E,
n ¼ 323; monthly, n ¼ 326).
Patient demographic and baseline ocular characteristics were
well balanced between the 2 treatment groups (Table 1). Overall,
the mean age of the patients was 75.2 years; 55.4% were women59
Figure 2. Diagram showing patient disposition (randomized set). Randomized set included all randomized patients to whom a randomization number was
assigned. Percentages were based on the total number of patients in the randomized set in the speciﬁc treatment group. AEs ¼ adverse events; T&E ¼ treat
and extend.
Ophthalmology Volume 125, Number 1, January 2018and 91.8% were white. At baseline, the mean BCVA was 60.0
letters, mean IOP was 15.0 mmHg, and mean CSFT was
500.8 mm. The baseline OCT, ﬂuorescein angiography, and color
fundus photography characteristics of the study eye were
comparable between the 2 treatment groups (Table 1).
Efﬁcacy Outcomes
The LS mean BCVA change from baseline improved by 6.2
ETDRS letters in the T&E group (n ¼ 320) and by 8.1 ETDRS
letters in the monthly group (n ¼ 323). The LS mean difference
between the treatment groups was 1.9 letters (95% conﬁdence
interval, 3.83 to 0.07; P < 0.001 for noninferiority). The mean
BCVA change from baseline to the end of study increased in the
T&E and monthly groups (Fig 3). Patients in both treatment groups
achieved a rapid gain in BCVA during the study; most of the
improvement occurred during the ﬁrst 6 months and was
maintained until the end of study (Fig 3). The proportion of
patients with categorical BCVA gain of 1 letter or more, 5 letters
or more, 10 letters or more, 15 letters or more, and 30 letters or
more (Fig 4A, available at www.aaojournal.org) and loss of
fewer than 5, fewer than 10, and fewer than 15 letters (Fig 4B,
available at www.aaojournal.org) and the percentage of patients
with BCVA of 73 letters or more from baseline to the end of
study (Fig 4C, available at www.aaojournal.org) were similar
between the treatment groups.
Anatomic Outcomes
The mean change in CSFT from baseline to the end of study was
similar between the groups (T&E, 169.2 mm [n ¼ 291];
monthly, 173.3 mm [n ¼ 287]), with a difference in LS means of
2.9 mm (95% conﬁdence interval, 14.76 to 20.53; P ¼ 0.748)
between the 2 treatment regimens (Fig 5). From baseline to the end
of study, intraretinal cysts and subretinal ﬂuid in the study eye were
resolved in 53.4% and 62.3% of patients treated with the
ranibizumab T&E regimen versus 49.3% and 60.1% of the
patients treated with the monthly regimen, respectively. The
proportion of patients with CNV leakage in the study eye at the
end of study was comparable between the treatment groups
(T&E, 18.7%; monthly, 17.1%). The mean change in CNV
leakage area from baseline to the end of study in the study eye
treated with the ranibizumab T&E regimen was 1.964 mm260(SD, 4.504 mm2) in 68 patients versus 2.266 mm2 (SD,
4.860 mm2) with the monthly regimen in 64 patients.
Treatment Exposure and Visits
The mean number of ranibizumab injections received was 8.7 (SD,
2.68) in the T&E group and 11.1 (SD, 2.43) in the monthly group
(Fig 6). In total, 80 patients (24.8%) in the T&E group received 12
injections. However, some of these patients were in the midst of an
extended treatment period toward the end of study or their
treatment had been extended once and then they returned to
monthly injections later. Twenty-three patients received 12 in-
jections of ranibizumab, but were extended to 6 weeks between
treatments; therefore, the proportion of patients with 12 monthly
injections was 17.6% (i.e., [80  23]/323 ¼ 57/323). A large
proportion of patients (61.9%) treated with the T&E regimen had a
maximum treatment interval of 8 weeks or more (Fig 7). The mean
number of postbaseline visits was 8.9 (SD, 2.56) for the T&E
regimen and 11.2 (SD, 2.37) for the monthly regimen, with an
average mean time between 2 consecutive visits of 40.1 days for
the T&E regimen and 28.5 days for the monthly regimen.
Safety Outcomes
Overall, 36.4% and 47.9% of the patients reported ocular AEs in
the study eye and nonocular AEs, respectively. The most common
ocular AEs reported in both treatment groups were IOP increased
(T&E, 8.4%; monthly, 8.6%), followed by conjunctival hemor-
rhage (T&E, 4.3%; monthly, 5.8%). Reduced VA was reported in
4.6% of the patients in the T&E group versus 3.7% in the monthly
group (Table 2). The most common nonocular AEs reported in
both treatment groups were nasopharyngitis (T&E, 5.6%;
monthly, 8.0%), hypertension (T&E, 7.1%; monthly, 4.0%),
inﬂuenza (T&E, 2.8%; monthly, 3.7%), and bronchitis (T&E,
2.5%; monthly, 3.7%; Table 2).
Overall, ocular serious adverse events (SAEs) in the study eye
were similar between the treatment groups (1.2% each). There were
only single reports of any ocular SAE of the study eye. Endoph-
thalmitis was reported in 1 patient (0.3%) in the monthly group
(Table 3). Overall, nonocular SAEs were reported in 11.4% of
patients (T&E, 11.1%; monthly, 11.7%). Five patients in the
T&E group (drug ineffective, n ¼ 2 [0.6%]; blindness, headache,
nAMD, retinal hemorrhage, and subretinal ﬂuid, n ¼ 1 each









Age (yrs), mean (SD) 75.3 (8.61) 75.2 (8.13)
Female gender (%) 55.4 55.4
White race (%) 91.6 92.0
VA (ETDRS letters),
mean (SD)
59.5 (13.21) 60.6 (13.92)
CSFT (mm), mean (SD) 504.0 (189.94) 497.7 (187.23)
IOP (mmHg), mean (SD) 14.9 (2.66) 15.1 (2.91)
Macular edema, no. (%)
Absent 52 (16.1) 51 (15.6)
Deﬁnite 269 (83.3) 275 (84.1)
Cannot grade 1 (0.3) 0 (0.0)
Missing 1 (0.3) 1 (0.3)
Presence of subretinal ﬂuid,
no. (%)
Yes 288 (89.2) 293 (89.6)
No 34 (10.5) 33 (10.1)
Cannot grade 0 (0.0) 0 (0.0)
Missing 1 (0.3) 1 (0.3)
Presence of cyst, no. (%)
Yes 180 (55.7) 161 (49.2)
No 142 (44.0) 165 (50.5)
Cannot grade 0 (0.0) 0 (0.0)
Missing 1 (0.3) 1 (0.3)
Area of lesion (mm2),
mean (SD)
6.5 (5.72) 6.2 (5.30)
Total area of leakage (mm2),
mean (SD)
5.9 (5.23) 5.6 (4.66)
Area of CNV (mm2),
mean (SD)
1.9 (2.29) 1.7 (1.74)
CNV secondary, no. (%)
AMD 310 (96.0) 316 (96.6)
Presence of ﬂuorescein leakage,
no. (%)
Yes 256 (79.3) 260 (79.5)
No 53 (16.4) 52 (15.9)
Cannot grade 1 (0.3) 3 (0.9)
Not applicable 11 (3.4) 10 (3.1)
Missing 2 (0.6) 2 (0.6)
Presence of hemorrhage, no. (%)
Yes 168 (52.0) 147 (45.0)
No 153 (47.4) 176 (53.8)
Cannot grade 0 (0.0) 2 (0.6)
Missing 2 (0.6) 2 (0.6)
Type of lesion, no. (%)
100% classic 86 (26.6) 88 (26.9)
Predominantly classic 27 (8.4) 23 (7.0)
Minimally classic 33 (10.2) 11 (3.4)
Occult with no classic
component
138 (42.7) 171 (52.3)
Cannot grade 17 (5.3) 13 (4.0)
Other 9 (2.8) 10 (3.1)
Not applicable 11 (3.4) 9 (2.8)
Missing 2 (0.6) 2 (0.6)
AMD ¼ age-related macular degeneration; CNV ¼ choroidal
neovascularization; CSFT ¼ central subﬁeld thickness; ETDRS ¼ Early
Treatment Diabetic Retinopathy Study; IOP ¼ intraocular pressure;
SD ¼ standard deviation; VA ¼ visual acuity.
Randomized set included all randomized patients to whom a randomization
number was assigned. Percentages were based on the total number of
patients in the randomized set in the speciﬁc treatment group.
*Number of patients at enrollment.
Figure 3. Graph showing the mean change in best-corrected visual acuity
(BCVA) from baseline to the end of study (full analysis set). Full analysis
set included all patients to whom treatment regimen was assigned. Note
that patients in the treat-and-extend (T&E) group were not seen at ﬁxed
intervals after the second visit. The monthly BCVA values shown in the
graph are nominal sliding averages derived by the following rule: for a given
month, the nearest value within 2 weeks was used. If there were 2 values
within that period, the mean was used. End of study refers to month 12 for
patients randomized to the monthly arm and to the last scheduled visit
(either month 12 or month 12.5) for patients who were randomized to the
T&E arm. *Number of patients in the full analysis set. **Number of pa-
tients evaluated at baseline and month 12. ETDRS ¼ Early Treatment
Diabetic Retinopathy Study; SE ¼ standard error; VA ¼ visual acuity.
Silva et al  T&E vs. Monthly Ranibizumab in nAMD[0.3% each]), and 3 patients in the monthly group (drug ineffective,
n ¼ 2 [0.6%]; macular hole, n ¼ 1 [0.3%]) discontinued the study
drug because of ocular AEs, whereas 1 patient in each treatment
group (T&E: retinal hemorrhage, n ¼ 1 [0.3%]; monthly:
macular hole, n ¼ 1 [0.3%]) discontinued the study drug because
of ocular SAEs. The number of deaths was similar between the 2Figure 5. Graph showing the mean change in central subﬁeld thickness
(CSFT) from baseline to the end of study (full analysis set). Full analysis set
included all patients to whom treatment regimen was assigned. Note that
patients in the treat-and-extend (T&E) group were not seen at ﬁxed in-
tervals after the second visit. The monthly CSFT values shown in the graph
are nominal sliding averages derived by the following rule: for a given
month, the nearest value within 2 weeks was used. If there were 2 values
within that period, the mean was used. End of study refers to month 12 for
patients randomized to the monthly arm and to the last scheduled visit
(either month 12 or month 12.5) for patients who were randomized to the
T&E arm. *Number of patients in the full analysis set. **Number of patients
evaluated both at baseline and the end of study (full analysis set).
61
Figure 6. Bar graph showing the proportion of patients receiving a given number of ranibizumab injections in the study eye during the 1-year study, shown
for each treatment group: treat and extend (T&E) and monthly (safety set). In the T&E group, approximately 60% of the patients received 6 to 10 in-
jections. Safety set consisted of all patients who received at least 1 application of study treatment and had at least 1 postbaseline safety assessment. Per-
centages are based on the number of patients in the safety set in the speciﬁc treatment group. *Includes 23 patients who received 12 injections, but were
extended to 6 weeks; therefore the percentage of patients with 12 injections was 80  23/323 patients ¼ 57 [17.65%]. SD ¼ standard deviation.
Ophthalmology Volume 125, Number 1, January 2018treatment groups (3 deaths in the T&E group and 4 deaths in the
monthly group). No deaths were suspected by the investigator to
be related to the study treatment. In summary, the incidence of
ocular and nonocular AEs and SAEs and deaths was similar, and
no new safety signals were observed in either of the 2 treatment
groups.
Discussion
The TREND study is one of the largest randomized clinical
trials in patients with nAMD to evaluate the efﬁcacy of the
T&E dosing regimen versus monthly therapy. Ranibizumab
0.5 mg administered according to a T&E dosing regimen
was noninferior (P < 0.001) and clinically comparable withFigure 7. Bar graph showing the longest intravitreal injection treatment
interval achieved during 1 year of ranibizumab treat-and-extend (T&E)
regimen (full analysis set). The longest possible interval, per protocol, was
12 weeks. Full analysis set included all patients to whom treatment regimen
was assigned.
62a monthly regimen in improving VA from baseline to the
end of study. The LS mean BCVA change from baseline to
the end of study was 6.2 letters in the T&E group and 8.1
letters in the monthly group. Patients in both treatment
groups achieved a similar and rapid gain in BCVA during
the study, with most of the improvement occurring during
the ﬁrst 6 months and generally maintained until the end of
study. These functional outcomes were supported further by
the corresponding anatomic improvements. These compa-
rable results were achieved with approximately 2.5 fewer
mean ranibizumab injections in the T&E group than the
monthly group (8.7 vs. 11.1) and with a reduced mean
number of corresponding visits (8.9 vs. 11.2). The average
duration between the visits was 40.1 days in the T&E group
and 28.5 days in the monthly group. In the T&E group,
51.7% of the patients received 6 to 9 injections. These gains
in VA with the ranibizumab T&E regimen in TREND were
comparable with those observed with the monthly regimen
in the pivotal Minimally Classic/Occult Trial of the Anti-
VEGF Antibody Ranibizumab in the Treatment of Neo-
vascular Age-Related Macular Degeneration, but with fewer
clinic visits and injections over 12 months.10
Previous studies have suggested that a large proportion of
patients with nAMD maintain VA gains with individualized
PRN treatment regimens.12,13,16e20 However, monthly
monitoring is not always required for successful treatment.
Variations in retreatment requirements of patients indicate
that monthly or frequent monitoring may not be necessary.
The T&E regimen considers these varying patient re-
quirements, thus allowing for a tailored follow-up schedule.
Several retrospective and prospective studies have shown
that the ranibizumab T&E regimen provides sustained im-
provements in VA with an average of 9.6 letters in an
average of 8.1 injections in the ﬁrst year of treatment, thus
Table 2. Proportion of Patients with Ocular and Nonocular
Adverse Events Regardless of Study Drug Relationship (2% in








Ocular AEs, total 116 (35.9) 120 (36.8)
IOP increased 27 (8.4) 28 (8.6)
Conjunctival hemorrhage 14 (4.3) 19 (5.8)
Visual acuity reduced 15 (4.6) 12 (3.7)
Conjunctivitis 10 (3.1) 6 (1.8)
Eye pain 10 (3.1) 5 (1.5)
Cataract 7 (2.2) 7 (2.1)
Retinal hemorrhage 6 (1.9) 8 (2.5)
Dry eye 6 (1.9) 7 (2.1)
Nonocular AEs, total 150 (46.4) 161 (49.4)
Nasopharyngitis 18 (5.6) 26 (8.0)
Hypertension 23 (7.1) 13 (4.0)
Inﬂuenza 9 (2.8) 12 (3.7)
Bronchitis 8 (2.5) 12 (3.7)
Pneumonia 7 (2.2) 5 (1.5)
AE ¼ adverse event; IOP ¼ intraocular pressure.
Data are no. (%). Safety set included all patients who underwent at least 1
application of study treatment and had at least 1 postbaseline safety
assessment. A patient with multiple incidences of an AE having undergone
1 treatment was counted only once in the AE category. Adverse events
with a start date on or after the date of ﬁrst administration of study
treatment in the study eye were counted.
Boldface values indicate total safety events.
Table 3. Proportion of Patients (%) with Ocular (1 Patients in
Any Group) and Nonocular (2 Patients in Any Group) Serious
Adverse Events Regardless of Study Drug Relationship, by








Ocular SAEs, total 4 (1.2) 4 (1.2)
Corneal erosion 1 (0.3) 0 (0.0)
Corneal inﬁltrates 1 (0.3) 0 (0.0)
Dacryostenosis acquired 0 (0.0) 1 (0.3)
Endophthalmitis 0 (0.0) 1 (0.3)
IOP increased 0 (0.0) 1 (0.3)
Macular hole 0 (0.0) 1 (0.3)
Retinal detachment 1 (0.3) 0 (0.0)
Retinal hemorrhage 1 (0.3) 0 (0.0)
Retinal tear 1 (0.3) 0 (0.0)
Vitreous hemorrhage 1 (0.3) 0 (0.0)
Nonocular SAEs, total 36 (11.1) 38 (11.7)
Pneumonia 4 (1.2) 2 (0.6)
Transient ischemic attack 3 (0.9) 1 (0.3)
Chronic obstructive
pulmonary disease
2 (0.6) 1 (0.3)
Dyspnea 2 (0.6) 1 (0.3)
Bronchitis 2 (0.6) 0 (0.0)
Cerebrovascular accident 0 (0.0) 2 (0.6)
Femur fracture 2 (0.6) 0 (0.0)
Hypotension 2 (0.6) 0 (0.0)
Lung neoplasm malignant 0 (0.0) 2 (0.6)
Myocardial infarction 2 (0.6) 0 (0.0)
Sciatica 0 (0.0) 2 (0.6)
Vertigo 2 (0.6) 0 (0.0)
Death 3 (0.9) 4 (1.2)
IOP ¼ intraocular pressure; SAE ¼ serious adverse event.
Data are no. (%). Safety set included all patients who underwent at least 1
application of study treatment and had at least 1 postbaseline safety
assessment. A patient with multiple occurrences of an SAE having un-
dergone 1 treatment was counted only once in the SAE category. Serious
adverse events with start date on or after the date of ﬁrst administration of
study treatment in the study eye were counted.
Boldface values indicate total safety events.
Silva et al  T&E vs. Monthly Ranibizumab in nAMDoptimizing injection and monitoring frequencies.1,17e25
These outcomes also were observed to be comparable
with the large, real-world observational studies conducted in
patients with nAMD.26,27 The results from the TREND
study with the ranibizumab T&E regimen were comparable
with those observed by Toalster et al17 and in the Lucentis
Compared to Avastin Study,18 in which the mean increase
in BCVA was 7.0 letters and 8.2 letters, respectively, with
a mean of 8 ranibizumab injections each over 12 months.
Similarly, the proportion of patients with 15 letters or
more of VA gain (25.8%) in the T&E group was
comparable with that observed in the Lucentis Compared
to Avastin Study (26.7%)18 and the study by Gupta et al16
(32.0%). When comparing the TREND results with
another randomized clinical study (TREX) which also
compared a monthly regimen with a T&E regimen, similar
BCVA gains were observed with a monthly regimen in
both studies (TREND, 8.1 letters; TREX, 9.2 letters),
although average gains were higher with the T&E regimen
in the TREX study (TREND, 6.2 letters; TREX, 10.5
letters).19 However, these data should be interpreted with
caution considering the obvious limitations of cross-trial
comparisons.
A similar proportion of patients in the 2 treatment groups
in the TREND study reported ocular AEs (36.4% overall)
and nonocular AEs (47.9% overall) in the study eye. During
the study, 3 deaths were reported in the T&E group and 4
were reported in the monthly group; however, none were
suspected to be related to the study medication by the
investigator. Over the course of the study, the incidence ofocular SAEs (1.2% in each treatment group) and nonocular
SAEs (11.1% in the T&E group and 11.7% in the monthly
group) were similar. Overall, the safety ﬁndings were
consistent with the well-established safety proﬁle of
ranibizumab.28
This study was limited by a follow-up period of 12
months. Further reduction on treatment burden may have
been shown in a longer study period. Despite this limitation,
the study met its primary end point by demonstrating similar
efﬁcacy with fewer injections and visits in patients treated
with the T&E regimen. In addition, the adequate sample size
of patients included in this study adds to the evidence base
of the existing literature supporting T&E as an important
alternative option to monthly ranibizumab treatment.13,17e20
Speciﬁcally, the titrated, individualized extension of visit
intervals during the ﬁrst year of a T&E regimen may provide
valuable input for case management with a minimized
treatment burden in subsequent years.
It is well established that good results can be obtained
with the PRN regimen in a controlled clinical study.11e1463
Ophthalmology Volume 125, Number 1, January 2018However, in a real-world clinical setting, improvement and
maintenance of these gains often is lower because of a
reduced number of retreatments.29 Data from uncontrolled,
retrospective analyses have shown that the PRN regimen
leading to fewer than 5 injections in the ﬁrst year are
insufﬁcient to sustain VA improvements.30e32 These ﬁnd-
ings emphasize the need for more aggressive treatment with
a higher frequency of treatment regimens or with stringent
retreatment criteria within PRN regimens to avoid under-
treatment or irreversible loss of vision. In contrast, based on
clinical reports, a proactive T&E regimen has been shown to
provide better functional outcomes than a PRN regimen
with fewer treatment visits and with a mean of approxi-
mately 6 to 8 injections during the ﬁrst year of
treatment.18,23,33,34
To summarize, ranibizumab 0.5 mg administered ac-
cording to a T&E regimen was statistically noninferior and
clinically comparable with a ranibizumab monthly regimen
in improving VA from baseline to the end of study in pa-
tients with nAMD. Patients in both treatment groups ach-
ieved a rapid initial gain in BCVA, which was maintained
up to the end of study. No new safety signals were identiﬁed
with ranibizumab treatment during the study. Ranibizumab
is the ﬁrst licensed anti-VEGF therapy with a label that al-
lows customized or individualized dosing treatment
approach of T&E from the ﬁrst year. The T&E approach
may be a viable option for patients, allowing maintenance of
visual gains with less than monthly monitoring. It offers
opportunities to individualize patient management while
minimizing treatment burden and costs associated with pa-
tient care.33
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